Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California, USA.
Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA.
Stem Cells Transl Med. 2019 Aug;8(8):758-767. doi: 10.1002/sctm.18-0279. Epub 2019 Apr 24.
As common chemotherapeutic agents are associated with an increased risk of acute and chronic cardiovascular complications, a new clinical discipline, cardio-oncology, has recently emerged. At the same time, the development of preclinical human stem cell-derived cardiovascular models holds promise as a more faithful platform to predict the cardiovascular toxicity of common cancer therapies and advance our understanding of the underlying mechanisms contributing to the cardiotoxicity. In this article, we review the recent advances in preclinical cancer-related cardiotoxicity testing, focusing on new technologies, such as human induced pluripotent stem cell-derived cardiomyocytes and tissue engineering. We further discuss some of the limitations of these technologies and present future directions. Stem Cells Translational Medicine 2019;8:758&767.
随着常见化疗药物与急性和慢性心血管并发症风险增加相关，最近出现了一个新的临床学科，即肿瘤心脏病学。与此同时，临床前人类干细胞衍生的心血管模型的发展有望成为更准确的平台，用于预测常见癌症治疗的心血管毒性，并深入了解导致心脏毒性的潜在机制。在本文中，我们回顾了临床前癌症相关性心脏毒性检测的最新进展，重点介绍了新技术，如人类诱导多能干细胞衍生的心肌细胞和组织工程。我们进一步讨论了这些技术的一些局限性，并提出了未来的发展方向。《Stem Cells Translational Medicine》2019 年；8:758&767.
